BeyondSpring Inc.

News & Events

Press Releases

In The Media

1. BeyondSpring Files 2024 Annual Report on Form 10-K

   GlobeNewswire MAR 27, 2025 7:05 AM EDT
   FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (...
   READ ARTICLE

2. BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

   GlobeNewswire MAR 27, 2025 7:00 AM EDT
   Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine , ...
   READ ARTICLE

3. BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

   GlobeNewswire JAN 28, 2025 7:00 AM EST
   FLORHAM PARK, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (&...
   READ ARTICLE

4. SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

   GlobeNewswire JAN 28, 2025 7:00 AM EST
   KING OF PRUSSIA, Pa., Jan. 28, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. (“S...
   READ ARTICLE

5. BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

   GlobeNewswire NOV 11, 2024 8:00 AM EST
   FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (&...
   READ ARTICLE

6. BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

   GlobeNewswire SEP 16, 2024 7:00 AM EDT
   FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (...
   READ ARTICLE

7. BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

   GlobeNewswire SEP 16, 2024 7:00 AM EDT
   FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (...
   READ ARTICLE

8. BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine

   GlobeNewswire SEP 10, 2024 7:00 AM EDT
   - Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk r...
   READ ARTICLE

9. BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

   GlobeNewswire SEP 3, 2024 7:00 AM EDT
   FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (...
   READ ARTICLE

10. SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

    GlobeNewswire AUG 6, 2024 7:00 AM EDT
    The SEED-Eisai Research Collaboration leverages Eisai’s leading expertise in neurodegenera...
    READ ARTICLE